Amicus Therapeutics Reports Strong Q1 2025 Growth

Amicus Therapeutics ( (FOLD) ) has released its Q1 earnings. Here is a breakdown of the information Amicus Therapeutics presented to its investors.

Amicus Therapeutics, a global biotechnology company, focuses on developing and commercializing innovative treatments for rare diseases, leveraging its expertise to address unmet medical needs in this niche sector.

In its first quarter of 2025, Amicus Therapeutics reported a total revenue of $125.2 million, marking a 15% increase year-over-year at constant exchange rates. The company also announced strategic expansions, including the in-licensing of DMX-200 for rare kidney disease, aiming to enhance its portfolio and market potential in the U.S.

Key financial highlights include a 5% increase in Galafold sales and a significant 90% rise in Pombiliti + Opfolda sales, driven by new patient starts and market expansions. The company maintained its guidance for Galafold and adjusted its revenue growth expectations for Pombiliti + Opfolda to 50-65% at CER. Operating expenses decreased slightly, and the GAAP net loss narrowed to $21.7 million compared to the previous year.

Amicus Therapeutics continues to focus on expanding its market presence with regulatory approvals in Canada and Australia for Pombiliti + Opfolda and a new manufacturing agreement in the U.S. The company also secured a licensing agreement with Dimerix for DMX-200, targeting a rare kidney disease with significant unmet needs.

Looking ahead, Amicus remains committed to achieving GAAP profitability in the second half of 2025 and anticipates continued revenue growth, driven by strong demand for its existing products and strategic portfolio expansions.